According to a filing with the U.S. Securities and Exchange Commission dated November 5, 2025, Renaissance Group disclosed a new position in Halozyme Therapeutics. The fund purchased 478,735 shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback